Clinical trials: Nausea and Vomiting Chemotherapy-Induced
Carcinoma, Non-small Cell Lung
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up to now it was still unknown the CINV control…
- Trial name
- NCT02161991
- Testing
- Aprepitant
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Hunan Province Tumor Hospital
Vomiting, Nausea
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
The purpose of this study is to compare the efficacy and safety of ramosetron plus dexamethasone injection with granisetron plus dexamethasone injection for the prevention of chemotherapy-induced vomiting and nausea.
- Trial name
- NCT00272285
- Testing
- Ramosetron, Granisetron
- Where
- 2 sites in Taiwan
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Inc
Chemotherapy-induced Nausea and Vomiting, Colorectal Cancer
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
Addition of aprepitant, an NK1 receptor antagonist to a 5-HT3 receptor antagonist and dexamethasone regimen was shown to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic…
- Trial name
- NCT02909478
- Testing
- Aprepitant+Tropisetron, Dexamethasone+Tropisetron
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Sun Yat-sen University
Breast Carcinoma
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving…
- Trial name
- NCT03367572
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride
- Where
- 18 sites in United States
- Volunteers
- 1,363 people
- Sponsor
- University of Rochester NCORP Research Base
Chemotherapy-Induced Nausea and Vomiting, Non Hodgkin's Lymphoma
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
This is an open-label, multicenter phase II study in patients with aggressive Non Hodgkin Lymphoma scheduled to receive moderately emetogenic polychemotherapy (according to modified Hesketh classification for antiemetic therapy).
- Trial name
- NHLPal (NCT01018758)
- Testing
- Palonosetron
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Nausea With Vomiting Chemotherapy-Induced
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV).
- Trial name
- NCT04150614
- Testing
- Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Illinois Chicago
Nausea and Vomiting Chemotherapy-Induced
Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy
The goal of this observational study is to evaluate the associations between patient-directed medical cannabis use and chemotherapy-induced nausea and vomiting (CINV), as well as other treatment-related symptoms, among patients…
- Trial name
- MOSAIC (NCT07374939)
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Rochester
Brain Cancer
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
1. Primary Objective: To determine the efficacy and tolerability of palonosetron and dexamethasone in preventing acute CINV in brain tumor patients during the first 24 hours of receiving Irinotecan /Bevacizumab regimens. 2.
- Trial name
- NCT00636805
- Testing
- Palonosetron (Aloxi) and Dexamethasone
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
The goal of this clinical trial is to learn if medroxyprogesterone acetate oral suspension (Meishiya®) works to prevent nausea and vomiting caused by single-day moderate to high emetogenic chemotherapy (MEC/HEC) in the…
- Trial name
- NCT07124195
- Testing
- Medroxyprogesterone acetate oral suspension, high antiemetic regimen, moderate antiemetic regimen
- Where
- China
- Volunteers
- 126 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Chemotherapy-induced Nausea and Vomiting, Lung Cancer
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
Chemotherapy induced nausea and vomiting (CINV) is a common adverse effect in treatment of cancer, which influences the quality of life and adherence to treatment of patients and leads to dehydration, malnutrition and even death.
- Trial name
- NCT03571126
- Testing
- Olanzapine
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- Zunyi Medical College
Nausea and Vomiting Chemotherapy-Induced, Meditation Training
Meditation for Chemotherapy-Induced Nausea and Vomiting in Women With Breast Cancer
This randomized clinical trial aimed to evaluate the effectiveness of Twin Hearts Meditation in reducing chemotherapy-induced nausea and vomiting among women with breast cancer undergoing chemotherapy.
- Trial name
- Breast Cancer (NCT07470619)
- Testing
- Twin Heart Meditation
- Where
- Cyprus
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Near East University, Turkey
Neoplasms, Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting
This purpose of this study is to evaluate the efficacy and safety of single and repeated doses of palonosetron hydrochloride in preventing nausea and vomiting caused by moderate and highly emetogenic chemotherapy in patients.
- Trial name
- ESPNV (NCT01481831)
- Testing
- Palonosetron Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 599 people
- Sponsor
- Shanghai Changzheng Hospital
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)
The goal of this clinical trial is to evaluate whether aromatherapy inhaler sticks can reduce nausea and vomiting in patients receiving chemotherapy as part of their stem cell transplant treatment.
- Trial name
- Aroma-CINV (NCT07209501)
- Testing
- Aromatherapy inhaler
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Prevention of Unmitigated Chemotherapy-induced Emesis
Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to patient care and continues to decrease quality of life.
- Trial name
- PUCE (NCT03996863)
- Testing
- Otoband
- Where
- United States
- Sponsor
- Otolith Labs
Oncology, Nausea and Vomiting Chemotherapy-Induced
The Effect of Using Interactive Mobile Application for the Management of Chemotherapy- Induced Nausea and Vomiting in Children
The aim of this study was to develop an interactive mobile application and to investigate the effect of this application on the management of nausea and vomiting symptoms by using it during chemotherapy treatment.
- Conditions
- Oncology, Nausea and Vomiting Chemotherapy-Induced, Pediatric Cancer, Mobile Application
- Trial name
- NCT04693832
- Testing
- 5inD
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people
- Sponsor
- Trakya University
Chemotherapy-induced Nausea and Vomiting, Pediatric Cancer
Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting
The goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric oncology patients.
- Trial name
- NCT06120764
- Testing
- guided imagery
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Baskent University
Chemotherapy-Induced Nausea and Vomiting, Lung Cancer
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (CINV).
- Trial name
- NCT02445872
- Testing
- Aprepitant, Palonosetron, Dexamethasone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang University
Chemotherapy-induced Nausea and Vomiting
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients…
- Trial name
- AOPDPCINV (NCT02484911)
- Testing
- Olanzapine, Aprepitant, Palonosetron
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Childhood Cancer, Nausea with Vomiting Chemotherapy-Induced
Predict CHimio-or Radiation-induced NAusea and Vomiting in Children/adolescents Treated for Cancer
Chemo- or radiation-induced nausea and vomiting (CRVN) is one of the most frequent and feared side effects. It is a symptom that is few or not at all evaluated.
- Trial name
- PaNACHE (NCT06869005)
- Testing
- BARF scale
- Where
- 5 sites in France
- Volunteers
- 150 people
- Sponsor
- Rennes University Hospital
Liver Cancer, Liver Metastasis
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
Objectives: This protocol is part of a larger grant funded by the NCI to create an international research center to study Traditional Chinese Medicine (TCM).
- Trial name
- NCT00430313
- Testing
- Electro-Stimulation of Yongquan (K1) Acupoint
- Sponsor
- M.D. Anderson Cancer Center